US · AYTU · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Aytu BioPharma, Inc. (AYTU) intrinsic value and stock valuation
$2.66as of 2026-11-21 · Mkt cap 25.33M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Aytu BioPharma, Inc. DCF and intrinsic value
InvestorsCraft values AYTU with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from AYTU’s statements →
Aytu BioPharma, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M |
| Operating income | -$-7.83M | -$-1.59M | -$-17.07M | -$-109.91M | -$-58.87M |
| Net income | -$-13.56M | -$-15.84M | -$-17.05M | -$-108.78M | -$-58.29M |
| EPSd | -$-2.16M | -$-2.86M | -$-5.1M | -$-74M | -$-69.39M |
| Operating cash flow | -$-1.94M | -$-1.39M | -$-5.13M | -$-28.82M | -$-25.96M |
| Capital expenditure | -$-3.23M | -$-330K | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-5.17M | -$-1.72M | -$-5.13M | -$-28.82M | -$-25.96M |
| Total assets | $124.2M | $118.9M | $137.8M | $137.6M | $265.7M |
| Total debt | $22.9M | $16.4M | $30.4M | $18.2M | $31M |
| Net debt | -$-8.02M | -$-3.59M | $7.44M | -$-1.17M | -$-18.68M |
| Total equity | $19M | $27.7M | $39.4M | $44.3M | $137.6M |
| Cash and short-term investments | $31M | $20M | $23M | $19.4M | $49.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M |
| Cost of revenue | $20.6M | $16.1M | $40.8M | $46.4M | $36.4M |
| Gross profit | $45.8M | $49.1M | $66.6M | $50.3M | $29.2M |
| Research and development expenses | $1.33M | $2.77M | $4.09M | $12.7M | $5.62M |
| Selling, general and administrative expenses | $38.3M | $42M | $70.1M | $69.9M | $55.8M |
| Other expenses | $14.1M | $5.84M | $9.52M | $77.7M | $26.6M |
| Operating expenses | $53.7M | $50.7M | $83.7M | $160.2M | $88.1M |
| Cost and expenses | $74.2M | $66.8M | $124.5M | $206.6M | $124.5M |
| Interest income | $0.00 | $0.00 | $0.00 | $10K | $0.00 |
| Interest expense | $3.7M | $4.79M | $4.96M | $147.5M | $0.00 |
| Depreciation and amortization | $5.38M | $6.72M | $8.81M | $10.2M | $9.2M |
| Ebitda | -$-4.67M | $1.41M | -$-3.27M | -$-27.96M | -$-29.04M |
| Operating income | -$-7.83M | -$-1.59M | -$-17.07M | -$-109.91M | -$-58.87M |
| Total other income/expenses, net | -$-5.92M | -$-8.79M | $10K | $1.02M | $840K |
| Income before tax | -$-13.74M | -$-10.38M | -$-17.05M | -$-108.89M | -$-58.03M |
| Income tax expense | $440K | $2.14M | $0.00 | -$-110K | $260K |
| Net income | -$-13.56M | -$-15.84M | -$-17.05M | -$-108.78M | -$-58.29M |
| Weighted average shares outstanding | $6.28M | $5.54M | $3.34M | $1.47M | $840K |
| Weighted average diluted shares outstanding | $6.28M | $5.54M | $3.34M | $1.47M | $840K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $31M | $20M | $23M | $19.4M | $49.7M |
| Net receivables | $31.2M | $23.5M | $28.9M | $21.7M | $28.2M |
| Inventory | $11.4M | $12.1M | $12M | $10.9M | $16.3M |
| Total current assets | $79.2M | $61.9M | $72.8M | $59.9M | $105.2M |
| Property, plant and equipment, net | $1.59M | $1.52M | $3.87M | $6.3M | $8.7M |
| Goodwill and intangible assets | $42.2M | $52.5M | $59M | $70.6M | $151.3M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | -$-10.91M |
| Total non-current assets | $45M | $57M | $65M | $77.7M | $160.4M |
| Total assets | $124.2M | $118.9M | $137.8M | $137.6M | $265.7M |
| Accounts payable | $10.6M | $10.3M | $13.5M | $11M | $19.3M |
| Short-term debt | $11.1M | $4.96M | $8.74M | $3.91M | $25.5M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $57.2M |
| Total current liabilities | $63.1M | $62.2M | $69M | $64.4M | $109.4M |
| Long-term debt | $11.9M | $11.5M | $21.7M | $14.3M | $5.43M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | -$-11.15M |
| Total non-current liabilities | $42.2M | $28.9M | $29.5M | $28.9M | $18.7M |
| Capital lease obligations | $1.12M | $1.29M | $830K | $180K | $3.56M |
| Total liabilities | $105.2M | $91.1M | $98.5M | $93.3M | $128.1M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-333.54M | -$-319.97M | -$-304.13M | -$-287.08M | -$-178.3M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | -$0.00 | $0.00 |
| Total equity | $19M | $27.7M | $39.4M | $44.3M | $137.6M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | -$-10.91M |
| Total debt | $22.9M | $16.4M | $30.4M | $18.2M | $31M |
| Net debt | -$-8.02M | -$-3.59M | $7.44M | -$-1.17M | -$-18.68M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-13.56M | -$-15.84M | -$-17.05M | -$-108.78M | -$-58.29M |
| Depreciation and amortization | $5.38M | $6.72M | $8.81M | $10.2M | $9.2M |
| Stock-based compensation | $580K | $2.37M | $6.05M | $5.25M | $3.57M |
| Change in working capital | -$-5.73M | -$-4.66M | -$-5.8M | -$-10.86M | $1.68M |
| Accounts receivable | -$-7.63M | $5.2M | -$-7.15M | $6.53M | $1.54M |
| Inventory | $380K | -$-4.82M | -$-3.61M | $1.3M | $2.79M |
| Accounts payable | $290K | -$-2.08M | $2.38M | -$-7.68M | -$-3.25M |
| Net cash provided by operating activities | -$-1.94M | -$-1.39M | -$-5.13M | -$-28.82M | -$-25.96M |
| Investments in property, plant and equipment | -$-230K | -$-330K | $0.00 | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | -$-10K | -$-3.18M | -$-480K |
| Net cash used for investing activities | -$-2.56M | -$-330K | -$-120K | -$-3.25M | -$-2.78M |
| Common stock issued | $14.8M | $3.47M | $15.6M | $11.7M | $40.2M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $15.4M | -$-1.26M | $8.87M | $1.53M | $30.3M |
| Net change in cash | $11M | -$-2.98M | $3.62M | -$-30.54M | $1.57M |
| Cash at end of period | $31M | $20M | $23M | $19.4M | $49.9M |
| Operating cash flow | -$-1.94M | -$-1.39M | -$-5.13M | -$-28.82M | -$-25.96M |
| Capital expenditure | -$-3.23M | -$-330K | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-5.17M | -$-1.72M | -$-5.13M | -$-28.82M | -$-25.96M |
Line items
Line items
Line items
About Aytu BioPharma, Inc.
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
- CEO
- Joshua R. Disbrow
- Employees
- 83
- Beta
- 0.25
Explore
Frequently asked questions
What is the intrinsic value of Aytu BioPharma, Inc. (AYTU)?
Aytu BioPharma, Inc. (AYTU) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is AYTU undervalued?
AYTU trades at a price of $2.66 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.